Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandon Aiman

Physician Assistant, Medical Anderson, IN Physician Assistant

NPI 1831124999 CMS profile 11041471

2101 Jackson St Ste 110, Medical Arts Building, Anderson, IN 46016

Open in the dashboard

General payments

$10,449

550 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Aiman of Anderson, IN is reported in the CMS Open Payments database as having received $10,449 across 550 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,082 103
2024 General $2,123 97
2023 General $2,048 103
2022 General $2,290 128
2021 General $1,905 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Aiman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brandon Aiman were reported at $2,082. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brandon Aiman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,905 $156 $41–$563 $132
2022 $2,290 $185 $55–$649 $149
2023 $2,048 $199 $58–$717 $160
2024 $2,123 $206 $62–$740 $164
2025 $2,082 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,997 91 payments
  2. GlaxoSmithKline, LLC. $1,718 125 payments
  3. Regeneron Healthcare Solutions, Inc. $784 30 payments
  4. Genzyme Corporation $754 42 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $497 21 payments
  6. Mallinckrodt Hospital Products Inc. $475 17 payments
  7. Grifols USA, LLC $460 19 payments
  8. Actelion Pharmaceuticals US, Inc. $355 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $355 18 payments
  10. Janssen Pharmaceuticals, Inc $339 22 payments
  11. Other $2,714 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,270 548 payments
  2. Education $179 2 payments
Products named General payments · program years 2021–2025
  1. FASENRA $1,046 39 payments
  2. TRELEGY ELLIPTA $901 69 payments
  3. TEZSPIRE $794 29 payments
  4. DUPIXENT Immunology $769 43 payments
  5. NUCALA $766 51 payments
  6. DUPIXENT Inflammation And Immunology $706 27 payments
  7. BREZTRI $546 16 payments
  8. GLASSIA $497 21 payments
  9. ACTHAR $475 17 payments
  10. Prolastin-C Liquid $414 16 payments
  11. Other $5,252 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,217

Median for Physician Assistant: 241

Drug cost

$208,575

Median for Physician Assistant: $4,110

Branded share of claims

48.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 105 $71,987
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 42 $38,420
Xarelto Rivaroxaban Brand 23 $27,945
Spiriva Respimat Tiotropium Bromide Brand 32 $16,369
Eliquis Apixaban Brand 13 $12,099
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 11 $7,049
Breo Ellipta Fluticasone/Vilanterol Brand 17 $6,822
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 36 $4,282
Symbicort Budesonide/Formoterol Fumarate Brand 17 $3,576
Albuterol Sulfate Hfa Albuterol Sulfate Brand 128 $3,509

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,284

Medicare's payments for the services billed

Medicare patients

21

Average age 73

Services billed

22

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 71%
Arthritis 57%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $216
  • GENZYME CORPORATION $171
$386 — —
Prolastin-C Liquid
  • Grifols USA, LLC $222
$222 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $210
$210 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $187
  • Amgen Inc. $21
$208 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $146
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

550 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record